Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 1 TO REGISTRATION STATEMENT - Citius Pharmaceuticals, Inc. | fs12018a1_citiuspharma.htm |
| EX-5.1 - OPINION OF WYRICK ROBBINS YATES & PONTON LLP - Citius Pharmaceuticals, Inc. | fs12018a1ex5-1_citiuspharma.htm |
| EX-4.7 - UNDERWRITER COMMON STOCK PURCHASE WARRANT - Citius Pharmaceuticals, Inc. | fs12018a1ex4-7_citiuspharma.htm |
| EX-4.6 - PRE-FUNDED COMMON STOCK PURCHASE WARRANT - Citius Pharmaceuticals, Inc. | fs12018a1ex4-6_citiuspharma.htm |
| EX-4.5 - COMMON STOCK PURCHASE WARRANT - Citius Pharmaceuticals, Inc. | fs12018a1ex4-5_citiuspharma.htm |
| EX-1.1 - CITIUS HCW UNDERWRITING AGREEMENT - Citius Pharmaceuticals, Inc. | fs12018a1ex1-1_citiuspharma.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Amendment No. 1 to the Registration Statement (No. 333-226395) on Form S-1 and related Prospectus of Citius Pharmaceuticals, Inc. of our report dated December 13, 2017, relating to the consolidated financial statements of Citius Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K for the year ended September 30, 2017.
We also consent to the reference to our Firm under the caption “Experts” in such Prospectus.
/s/ Wolf & Company, P.C.
Wolf
& Company, P.C.
Boston, Massachusetts
August 6, 2018